Efficacy of Mesalazine Combined With Biologics in the Treatment of Moderate to Severe Ulcerative Colitis
Status:
Not yet recruiting
Trial end date:
2025-01-15
Target enrollment:
Participant gender:
Summary
Endocopic remission rates of moderate to severe ulcerative colitis are low. Biologics
including Vedolizumab, infliximab, and adalimumab are effective in induction and maintainence
of ulcerative colitis. The role of 5-ASA in promoting a higher rate of endocsopic remission
is unclear. We aim to evaluate the efficacy of combination of 5-ASA and biologics in treating
ulcerative colitis.